| CAS ID: | 159351-69-6 |
| Molecular Formula: | C53H83NO14 |
| Molecular Weight: | 958.2 g/mol |
| Monoisotopic Mass: | 957.5814 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | AFINITOR DISPERZ | VOTUBIA | RAD001 | EVEROLIMUS | CERTICAN | ZORTRESS | AFINITOR |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1 | See All |
| InChI Key: | HKVAMNSJSFKALM-GKUWKFKPSA-N | |
| Smiles: | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO | See All |
| Molfile: | Download |
Reference Record 1
Reference Record 2
| PubMed ID | 26980426 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro | Fibrosis Disease | Abdominal fibrosis |
| Process I | |||
| Process II | fibroblasts proliferation | ||
| Process III | |||
| Mechanism | |||
Reference Record 3
| PubMed ID | 26054821 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro | Fibrosis Disease | Renal fibrosis |
| Process I | |||
| Process II | EMT | ||
| Process III | |||
| Mechanism | |||
Reference Record 4
| PubMed ID | 25862144 | Target ID | |
| Uniprot ID | Name | ||
| Model | human | Fibrosis Disease | Liver fibrosis |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Reference Record 5
Reference Record 6
| PubMed ID | 22427849 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Renal fibrosis |
| Process I | |||
| Process II | cells proliferation | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting mTOR | ||
Reference Record 7
Trial Record 1
| ClinicalTrial ID | NCT01079143 | Disease | Renal fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | March 2, 2010 | Last Verified | March 18, 2014 |
| Sponsor | Novartis Pharmaceuticals | ||
Trial Record 2
| ClinicalTrial ID | NCT02096107 | Disease | Renal fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | March 26, 2014 | Last Verified | August 8, 2018 |
| Sponsor | Medical University of South Carolina | ||
Trial Record 3
| ClinicalTrial ID | NCT01707849 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 16, 2012 | Last Verified | February 7, 2018 |
| Sponsor | Hospital Vall d'Hebron | ||
Trial Record 4
| ClinicalTrial ID | NCT00582738 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Terminated |
| First Received | December 28, 2007 | Last Verified | September 6, 2012 |
| Sponsor | Novartis Pharmaceuticals | ||
Trial Record 5
| ClinicalTrial ID | NCT01150097 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | June 24, 2010 | Last Verified | November 7, 2018 |
| Sponsor | Novartis Pharmaceuticals | ||
Trial Record 6
| ClinicalTrial ID | NCT02134899 | Disease | Renal fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 9, 2014 | Last Verified | December 10, 2018 |
| Sponsor | Assistance Publique - Hôpitaux de Paris | ||
Trial Record 7
| ClinicalTrial ID | NCT00622869 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | February 25, 2008 | Last Verified | May 27, 2013 |
| Sponsor | Novartis Pharmaceuticals | ||
| PubChem: | 6442177 |
| ChEMBL: | CHEMBL1908360 |